For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Plus Therapeutics Inc’s stock clocked out at $1.16, down -23.68% from its previous closing price of $1.52. In other words, the price has decreased by -$23.68 from its previous closing price. On the day, 3.22 million shares were traded. PSTV stock price reached its highest trading level at $1.3597 during the session, while it also had its lowest trading level at $1.1301.
Ratios:
To gain a deeper understanding of PSTV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.44 and its Current Ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, D. Boral Capital on March 17, 2025, initiated with a Buy rating and assigned the stock a target price of $9.
On January 25, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $8.
On October 16, 2020, Maxim Group started tracking the stock assigning a Buy rating and target price of $6.Maxim Group initiated its Buy rating on October 16, 2020, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Hawkins Richard J bought 4,000 shares for $1.50 per share. The transaction valued at 5,996 led to the insider holds 15,188 shares of the business.
Hawkins Richard J bought 6,285 shares of PSTV for $8,512 on Sep 12 ’24. The Director now owns 11,188 shares after completing the transaction at $1.35 per share. On Sep 11 ’24, another insider, Petersen Greg, who serves as the Director of the company, bought 12,500 shares for $1.35 each. As a result, the insider paid 16,875 and bolstered with 48,921 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 6839742 and an Enterprise Value of 7574426. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.35. Its current Enterprise Value per Revenue stands at 1.323 whereas that against EBITDA is -0.542.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.38, which has changed by -0.35555553 over the last 52 weeks, in comparison to a change of 0.06429911 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.67, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 4.74%, while the 200-Day Moving Average is calculated to be -14.98%.
Shares Statistics:
It appears that PSTV traded 16.13M shares on average per day over the past three months and 45990820 shares per day over the past ten days. A total of 11.79M shares are outstanding, with a floating share count of 11.48M. Insiders hold about 2.55% of the company’s shares, while institutions hold 16.02% stake in the company. Shares short for PSTV as of 1741910400 were 929630 with a Short Ratio of 0.06, compared to 1739491200 on 59847. Therefore, it implies a Short% of Shares Outstanding of 929630 and a Short% of Float of 16.07.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Plus Therapeutics Inc (PSTV) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.34 and -$0.34 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.85, with 2.0 analysts recommending between -$0.53 and -$1.16.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $1.48M. It ranges from a high estimate of $2.2M to a low estimate of $750k. As of the current estimate, Plus Therapeutics Inc’s year-ago sales were $1.68MFor the next quarter, 3 analysts are estimating revenue of $1.52M. There is a high estimate of $2.3M for the next quarter, whereas the lowest estimate is $750k.
A total of 3 analysts have provided revenue estimates for PSTV’s current fiscal year. The highest revenue estimate was $11.45M, while the lowest revenue estimate was $3M, resulting in an average revenue estimate of $6.48M. In the same quarter a year ago, actual revenue was $5.82M
